Thomas F. Gajewski

Thomas Gajewski practices at Comer Children's Hospital - Hyde Park in Chicago, Illinois.

Thomas Gajewski's NPI, 1194888610, was assigned on December 18, 2006. Thomas Gajewski graduated from University of Chicago, Pritzker School of Medicine in 1991. Thomas Gajewski holds Illinois license 036090751.

Thomas Gajewski's primary practice is Comer Children's Hospital - Hyde Park, at 5721 S Maryland Ave, Chicago, IL 60637 in Cook County. The practice phone is (773) 702-1530.

Thomas Gajewski's primary practice is Comer Children's Hospital - Hyde Park in Chicago, Illinois. Thomas Gajewski is also affiliated with University of Chicago Medical Center. The medical group on file is UChicago Medicine Physicians. Dmand AI also links Thomas Gajewski to 1 more hospital and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Thomas Gajewski practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Thomas Gajewski's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Thomas Gajewski is licensed in Illinois.

CMS data shows 107 Medicare services from Thomas Gajewski across 2 procedure codes in 2024, all of them office visits, for 47 Medicare patients. Medicare paid $8,616 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 47 Medicare patients who saw Thomas Gajewski in 2024. The largest group is 65 to 74, with 24 patients. 70% of them have high blood pressure, and 64% have high cholesterol. Their average risk score is 1.95, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Thomas Gajewski's median patient age at 74, with 39% women.

In 2024, Thomas Gajewski wrote 116 Medicare Part D claims for 17 patients. 53% of them were for generic drugs. CMS names the drug for 82 of them, across 4 drugs with 11 or more claims each, at $418,745 in total drug cost. In 2023, CMS named 78 claims across 4 drugs.

Thomas Gajewski accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Thomas Gajewski as offering telehealth.

Dmand AI links 163 papers to Thomas Gajewski, published from 2005 to 2025. 2016 was the busiest year, with 19. The most frequent topics are Immunotherapy, Tumor Microenvironment and Melanoma. Thomas Gajewski has published most often in J Immunother Cancer. Thomas Gajewski's most frequent co-authors are Jason J. Luke, MD, Sherin J. Rouhani, MD, PhD and Igor Puzanov, MD.

Dmand AI links Thomas Gajewski to 3 clinical trials. 1 is still active or recruiting. Conditions studied include Carcinoma, Merkel Cell, Neoplasms, Squamous Cell and Uveal Melanoma.

CMS Open Payments shows 159 general payments to Thomas Gajewski from 19 drug and device companies from 2016 to 2024. Consulting fees make up the largest share, 64% of the total. Incyte Corporation paid the most, $31,776. It also lists 3 research payments totaling $169 in 2016.

Thomas Gajewski graduated from University of Chicago, Pritzker School of Medicine in 1991.